Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 7,408 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tissue specimen Clear all

Conditions: Acute Respiratory Distress Syndrome
Interventions: Tenecteplase; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Macon, Georgia

Conditions: Sarcoma, Sarcoma Metastatic
Interventions: Olaparib, Trabectedin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ulcer, Wounds
Interventions: Active Leptospermum Honey (Medihoney), Collagenase; Device · Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cystectomy
Interventions: tissue procurement; Other
Lead sponsor: Tengion; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Generalized Lipodystrophy
Interventions: Mibavademab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Dallas, Texas

Conditions: Non-Muscle Invasive Bladder Cancer
Interventions: Questionnaires, Daily Mood Diaries, Urine Specimen Collection, Research Blood Draw, Utilize excess tissue from a standard of care procedure; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Enasidenib, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Buffalo, New York • East Hills, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets; Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 68 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 9
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia
Interventions: electrophysiology study and ablation with an Abbott Ablation Catheter; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 200 participants
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Rancho Mirage, California + 16 more

Conditions: Prostate Cancer
Interventions: flutamide, Zoladex, Lupron, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 222
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Cerebral Palsy
Interventions: Knotless barbed suture, Conventional suture; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Cancer
Interventions: Prehabilitation Intervention; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pulmonary Hypertension
Interventions: NX1011; Drug
Lead sponsor: NITROX, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more

Conditions: Tooth Loss
Interventions: allograft + x-link collagen membrane, xenograft + non-x-link collagen; Device
Lead sponsor: McGuire Institute; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Crohn Disease
Interventions: Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin, Methylprednisolone, Vedolizumab; Procedure · Drug
Lead sponsor: Aaron Etra; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: MR-Guided Transurethral US Ablation of Prostate Tissue; Device
Lead sponsor: Profound Medical Inc.; Other
Eligibility: 65 Years to 75 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver, Cancer
Interventions: wet heparinzed suction, Microsieve, No heparin flush, No microsieve; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Bariatric Surgery Candidate, Pain, Postoperative, Nausea and Vomiting, Postoperative, Opioid Use
Interventions: Intraoperative autonomic neural blockade (ANB), Laparoscopic Standard of Care Abdominal Wall Block; Procedure
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions: amifostine trihydrate, carboplatin, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 100 Years
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pedophilia
Interventions: leuprolide acetate; Drug
Lead sponsor: Schober, Justine, M.D.; Individual
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Sudden Unexplained Death Syndrome, Sudden Unexplained Death in Childhood
Interventions: Biospecimin Collection; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 11 Months to 100 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma
Interventions: Trabectedin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 15 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more

Conditions: Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
Interventions: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use; Procedure · Device · Drug
Lead sponsor: Black Tie Medical, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stevensville, Montana

Search by objective public record fields.

Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

MEDIHONEY® Gel Versus Collagenase for Wound Debridement

Study to Obtain Full Thickness Bladder Tissue From Subjects Undergoing Cystectomy Surgery

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Efficacy of Islet After Kidney Transplantation

Abbott Atrial Fibrillation Post Approval Study

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Knotless Versus Conventional Sutures for Wound Closure in Cerebral Palsy Multilevel Surgery

A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

An RCT Comparing Xenograft and Allograft for Ridge Preservation

Autologous Stem Cell Transplant for Crohn's Disease

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

Wet Heparinized Suction for Abdominal Cancer

Autonomic Neural Blockade in Bariatric Surgery

Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients

Lupron Sex Offender Therapy

Sudden Unexplained Death in Childhood (SUDC) Registry

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection